Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥ 15 mg may be overcome with subcutaneous administration - Schiff, MH; Jaffe, JS; Freundlich, B (Ann Rheum Dis, 2014)